Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Immunoglobulin Light-chain Amyloidosis 3Pleural Effusion, Malignant 2Amyloidosis 2Tuberous Sclerosis 1Skin Toxicity 1Ras-wildtype Colorectal Cancer 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Menstruation Disturbances 1Lymphoma, Non-Hodgkin 1Lymphangioleiomyomatosis 1Intracranial Aneurysm 1Hyperandrogenism 1Hemangioma, Cavernous 1Head and Neck Neoplasms 1Exanthema 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Arteriovenous Malformations 1Amyloidosis, Familial 1Advanced Malignant Neoplasm 1AA amyloidosis 1

Interventions

Sirolimus 6Everolimus 5saracatinib 1nintedanib 1Urination 1Sugars 1Simvastatin 1Resveratrol 1Octreotide 1Letrozole 1Imatinib Mesylate 1Hydroxychloroquine 1Glutamine 1Doxycycline 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphangioleiomyomatosis × Doxycycline × Clear all
NCT00989742 2015-12-02

Doxycycline In Lymphangioleiomyomatosis (LAM)

University of Nottingham

Phase 4 Completed
24 enrolled

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡